Search

Your search keyword '"Centre Hospitalier Universitaire de Dijon (CHU Dijon)"' showing total 16 results
Start Over Author "Centre Hospitalier Universitaire de Dijon (CHU Dijon)"
16 results on '"Centre Hospitalier Universitaire de Dijon (CHU Dijon)"'

1. First nationwide web-based surveillance system for influenza-like illness in pregnant women: participation and representativeness of the French G-GrippeNet cohort

Author

Solen Kernéis, Marc Bardou, Vittoria Colizza, Clément Turbelin, Odile Launay, Pierre-Yves Ancel, Caroline Guerrisi, Paul Loubet, François Goffinet, Béatrice Blondel, Thomas Hanslik, Isabelle Bonmarin, Thierry Blanchon, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Cochin Pasteur, Groupe hospitalier Broca - Hôtel-Dieu - CHU Cochin [APHP] - Assistance publique - Hôpitaux de Paris (AP-HP) - Institut National de la Santé et de la Recherche Médicale (INSERM), Recherche en Epidémiologie Obstétricale, Périnatale et Pédiatrique (Equipe 1 : EPOPé), Université Paris Descartes - Paris 5 (UPD5) - INSERM - Maternité Port-Royal - 6ème étage - Centre de Recherche en Epidémiologie et Statistique de Sorbonne-Paris-Cité (CRESS), REseau national d'Investigation clinique en VACcinologie (REIVAC), Institut Pasteur [Paris] - Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Cochin [APHP] - Hôtel-Dieu - Groupe hospitalier Broca - Institut National de la Santé et de la Recherche Médicale (INSERM) - Centre National de Gestion des Essais de Produits de Santé (CeNGEPS), Réseau Gynéco-Obstétrical des Centres d’Investigation Clinique (GO-CIC), Centre Hospitalier Universitaire de Dijon (CHU Dijon) - Institut National de la Santé et de la Recherche Médicale (INSERM) - AP-HP Hôpital universitaire Robert-Debré [Paris], Institut de Veille Sanitaire (INVS), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Institut Pierre Louis d'Epidémiologie et de Santé Publique ( iPLESP ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Service des Maladies Infectieuses, CHU Cochin [AP-HP], Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité ( CRESS (U1153 / UMR_A 1125) ), Institut National de la Recherche Agronomique ( INRA ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CIC Cochin Pasteur ( CIC 1417 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Réseau Gynéco-Obstétrical des Centres d’Investigation Clinique ( GO-CIC ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AP-HP Hôpital universitaire Robert-Debré [Paris], Institut de Veille Sanitaire ( INVS ), Service de Gynécologie et Obstétrique [Cochin], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), CIC Cochin Pasteur (CIC 1417), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), HAL-UPMC, Gestionnaire, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
020205 medical informatics, Health Status, 02 engineering and technology, 0302 clinical medicine, Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Pregnancy, Epidemiology, 0202 electrical engineering, electronic engineering, information engineering, Medicine, Public Health Surveillance, 030212 general & internal medicine, Young adult, Language, education.field_of_study, Surveillance, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, lcsh:Public aspects of medicine, Incidence, 3. Good health, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Web-based study, Cohort, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, France, Seasons, Research Article, Adult, medicine.medical_specialty, Population, Young Adult, 03 medical and health sciences, Environmental health, Influenza, Human, Humans, education, Internet, Influenza-like illness, business.industry, Public health, Public Health, Environmental and Occupational Health, lcsh:RA1-1270, medicine.disease, Health Surveys, Influenza, Socioeconomic Factors, Biostatistics, business
Abstract

International audience; Background: Pregnancy is a risk factor for severe influenza resulting in increased risks of hospitalisation and death in mothers and their new-borns. Our objective was to assess the representativeness and participation of French women to a new web-based collaborative tool for data collection and monitoring of Influenza Like Illness (ILI) during pregnancy. Methods: During the 2014/2015 influenza season, pregnant women living in metropolitan France were enrolled through a web platform (https://www.grippenet.fr/). Then throughout the season, participants were asked to report, on a weekly basis, if they had experienced symptoms of ILI. Representativeness was assessed by comparing the characteristics of participants to those of the French National Perinatal Survey. For each participant, the participation rate was the number of weekly questionnaires completed, divided by the length of follow-up (in weeks). Predictors of active participation (participation rate >15 %) were assessed by multivariate logistic regression. Results: A total of 153 women were enrolled. Participants were older (mean age 34 years vs. 29 years) and more highly educated (high school level 89 % versus 52 %) than the general population of pregnant women in France, but the sample did not differ on pregnancy-related characteristics (parity, history of hospitalisation during a previous pregnancy). The median rate of participation was high (78 %, interquartile range: 34–96). Higher educational level and participation to a previous GrippeNet.fr season were associated with active participation. Conclusion: Despite small sample size and lack of representativeness, the retention rate was high, suggesting that pregnant women are prone to adhere to a longitudinal follow-up of their health status via the Internet.

Published
2016

2. Prognosis and follow-up of psoriatic arthritis with peripheral joint involvement: Development of recommendations for clinical practice based on published evidence and expert opinion

Author

Alain Cantagrel, Alain Saraux, Thierry Schaeverbeke, Jacques Tebib, Bernard Combe, Carle Paul, Philippe Gaudin, Philippe Goupille, F. Lavie, Daniel Wendling, Emmanuelle Dernis, Carine Salliot, Jean-Francis Maillefert, René-Marc Flipo, Pascal Claudepierre, Xavier Le Loët, CHU Cochin [APHP], Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Lariboisière - Université Paris Diderot - Paris 7 (UP7), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Pellegrin, CHU Bordeaux [Bordeaux] - Groupe hospitalier Pellegrin, Génétique, Immunothérapie, Chimie et Cancer (GICC), Université François Rabelais - Tours - Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF) - CHU Grenoble, CHU Dijon, Centre Hospitalier Universitaire de Dijon (CHU Dijon), Hôpital Lapeyronie, Université Montpellier 1 (UM1) - Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier) - Hôpital Lapeyronie, Service de rhumatologie, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Service de rhumatologie [CHU Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, CHU Bordeaux [Bordeaux], Service d'immunologie et rhumatologie, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Rhumatologie, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Lapeyronie [Montpellier] (CHU), CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université de Tours-Centre National de la Recherche Scientifique (CNRS), and Cambefort, Jeanne

Subjects
MESH: Inflammation, [SDV]Life Sciences [q-bio], Delphi method, Alternative medicine, MESH: Monitoring, Physiologic, Arthritis, Recommendations, 0302 clinical medicine, MESH: Arthritis, Psoriatic, 030212 general & internal medicine, Practice Patterns, Physicians', MESH: Publishing, Evidence-Based Medicine, Follow-up, MESH: Follow-Up Studies, Prognosis, MESH: Predictive Value of Tests, 3. Good health, [SDV] Life Sciences [q-bio], MESH: Joints, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Psoriatic arthritis, Radiological weapon, Predictive value of tests, MESH: Expert Testimony, medicine.medical_specialty, MEDLINE, MESH: Prognosis, 03 medical and health sciences, Rheumatology, Predictive Value of Tests, medicine, Humans, MESH: Physician's Practice Patterns, Expert Testimony, Monitoring, Physiologic, Inflammation, Publishing, 030203 arthritis & rheumatology, MESH: Humans, business.industry, Arthritis, Psoriatic, Everyday clinical practice, Evidence-based medicine, medicine.disease, Radiography, Physical therapy, Joints, business, MESH: Evidence-Based Medicine, Follow-Up Studies
Abstract

International audience; Objectives: To develop recommendations about prognosis and follow-up of psoriatic arthritis (PsA) with peripheral joint involvement in everyday clinical practice. Methods: The strategy was as following: (a) The choice of five questions, by the scientific committee according to the Delphi method, considered as a basis for the recommendations; (b) the Systematic Literature Research based on Medline, Cochrane and abstracts from the annual meetings of SFR, EULAR and ACR. An expert committee composed with 68 rheumatologists elaborated and validated the recommendations, specifying the strength and the degree of agreement for each of them. Results: The questions selected were: (1) How can articular and cutaneous disease activity of PsA be assessed in usual clinical practice? (2) Which parameters are predictive for functional, radiological and fatal outcome in PsA? (3) Which clinical and biological parameters are useful for the follow-up of PsA? At which frequency? (4) Which X-rays are useful for the follow-up of PsA? At which frequency? (5) How can the response to treatments be assessed in PsA? The literature search identified 1181 abstracts and 123 articles were included and analyzed. Seven recommendations, whose strength ranged from B to D, were drafted and validated by a final vote of the expert committee. Conclusion: Seven recommendations about follow-up of patients with PsA for daily practice were developed. They can be expected to improve clinical practice uniformity and, in the longer term, to optimize the management of patients with PsA. (C) 2009 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

Published
2009

3. Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients

Author

Elisabeth André-Garnier, J. B. Bour, Jacques Izopet, Christophe Lemaire, S. Vallet, Adeline Pivert, Arielle R. Rosenberg, Pascale Trimoulet, Christopher Payan, E. Bouthry, Pascal Veillon, Sophie Alain, Dominique Bettinger, P. André, Alexandra Ducancelle, Catherine Gaudy-Graffin, Jean-Michel Pawlotsky, Françoise Stoll-Keller, Odile Petsaris, Cécile Henquell, Yazid Baazia, Bruno Pozzetto, Françoise Lunel-Fabiani, Florence Abravanel, Henia Saoudin, V. Thibault, Anne Signori-Schmuck, Sandrine Bertrais, Gisèle Lagathu, H. Le Guillou-Guillemette, Sylvie Larrat, S. Minjolle-Cha, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), SFR UA 4208 Interactions Cellulaires et Applications Thérapeutiques (ICAT), Université d'Angers (UA), CHU Limoges, Service de virologie [CHU Pitié-Salpêtrière], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Laboratoire de Virologie [Toulouse], CHU Toulouse [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Clermont-Ferrand, Hôtel-Dieu de Nantes, Laboratoire Universitaire de Biodiversité et Ecologie Microbienne (LUBEM), Université de Brest (UBO), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Avicenne, Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Laboratoire de Bactériologie de l'Hôpital de la Croix-Rousse, Hospices Civils de Lyon (HCL), Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH - U1259 Inserm - CHRU Tours ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Unit for Virus Host-Cell Interactions [Grenoble] (UVHCI), Centre National de la Recherche Scientifique (CNRS)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Université Joseph Fourier - Grenoble 1 (UJF), Biologie structurale des interactions entre virus et cellule hôte (UVHCI), Université Joseph Fourier - Grenoble 1 (UJF)-European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), CHU Pontchaillou [Rennes], Interaction virus-hôte et maladies du foie, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Henri Mondor, The authors thank A. Lefebvre, E. Muel, Y. Desille, I. Renard, A. Plages, A. Rodallec and W. Merrouche for their assistance in clinical data recording.Funding: This study was funded by the ANRS (Agence de Nationale de Recherche sur le VIH et les hépatites, appel d’offre Mars 2006)., PRES Université Nantes Angers Le Mans [UNAM], Interactions cellulaires et applications thérapeutiques (ICAT), Université d'Angers (UA) - CHU Angers - CRLCC Paul Papin - Institut National de la Santé et de la Recherche Médicale (INSERM) - Centre National de la Recherche Scientifique (CNRS), Service de virologie, Université Pierre et Marie Curie - Paris 6 (UPMC) - Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Pitié-Salpêtrière [APHP], Centre de Physiopathologie Toulouse Purpan, Université Paul Sabatier - Toulouse 3 (UPS) - IFR30 - IFR150 - Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Cochin [APHP], Université européenne de Bretagne (UEB) - Université de Bretagne Occidentale (UBO) - IFR148 ScInBioS, Centre Hospitalier Universitaire de Dijon (CHU Dijon), CHU Bordeaux [Bordeaux] - Groupe hospitalier Pellegrin, Hospices Civils de Lyon, Morphogénèse et antigénicité du VIH et du virus des Hépatites (MAVIVH), Institut National de la Santé et de la Recherche Médicale (INSERM) - Université François Rabelais - Tours - CHRU Tours, CHU Besançon, Université de Franche-Comté (UFC), Laboratoire de biologie structurale des interactions entre virus et cellule hôte, Université Joseph Fourier - Grenoble 1 (UJF) - Centre National de la Recherche Scientifique (CNRS), Université de Strasbourg - Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), European Molecular Biology Laboratory [Grenoble] (EMBL)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), CHU Henri Mondor [Créteil], and Jonchère, Laurent

Subjects
Adult, Liver Cirrhosis, Male, hepatitis C virus, Cirrhosis, Carcinoma, Hepatocellular, Hepatitis C virus, [SDV]Life Sciences [q-bio], Viral quasispecies, Hepacivirus, Biology, Viral Nonstructural Proteins, medicine.disease_cause, NS5A, Liver disease, Virology, Gene Duplication, Gene duplication, medicine, Prevalence, Humans, Aged, Hepatitis, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Sequence Analysis, RNA, cirrhosis, Liver Neoplasms, Hepatitis C, hepatocellular carcinoma, Hepatitis C, Chronic, Middle Aged, medicine.disease, digestive system diseases, 3. Good health, Protein Structure, Tertiary, [SDV] Life Sciences [q-bio], Mutagenesis, Insertional, Infectious Diseases, Cross-Sectional Studies, Hepatocellular carcinoma, RNA, Viral, Female, V3 domain, France, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Background The NS5A protein of the hepatitis C virus has been shown to be involved in the development of hepatocellular carcinoma. Objectives In a French multicenter study, we investigated the clinical and epidemiological features of a new HCV genotype 1b strain bearing a wide insertion into the V3 domain. Study Design We studied NS5A gene sequences in 821 French patients infected with genotype 1b HCV. Results We identified an uncharacterized V3 insertion without ORF disruption in 3.05% of the HCV sequences. The insertion comprised 31 amino-acids for the majority of patients; 3 patients had 27 amino-acids insertions and 1 had a 12 amino-acids insertion. Sequence identity between the 31 amino-acids insertions and the V3 domain ranged from 48 to 96% with E-values above 4e-5, thus illustrating sequence homology and a partial gene duplication event that to our knowledge has never been reported in HCV. Moreover we showed the presence of the duplication at the time of infection and its persistence at least during 12 years in the entire quasispecies. No association was found with extrahepatic diseases. Conversely, patients with cirrhosis were two times more likely to have HCV with this genetic characteristic (p=0.04). Moreover, its prevalence increased with liver disease severity (from 3.0% in patients without cirrhosis to 9.4% in patients with both cirrhosis and HCC, p for trend=0.045). Conclusions We identified a duplicated V3 domain in the HCV-1b NS5A protein for the first time. The duplication may be associated with unfavorable evolution of liver disease including a possible involvement in liver carcinogenesis

Published
2015

4. Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRβ-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique

Author

C. Charrin, Anne Hagemeijer, Carole Barin, M J Mozzicconacci, Barbara Cauwelier, Christine Lefebvre, Bruno Verhasselt, Isabelle Luquet, M.J. Gregoire, Philippe Jonveaux, Hélène Cavé, Barbara De Moerloose, Christine Terré, Kim De Keersmaecker, Anne De Paepe, G Plessis, F Sigaux, Nicole Dastugue, Bruce Poppe, Michel Lessard, B Laurence, Laurent Mauvieux, Hélène Antoine-Poirel, Marina Lafage-Pochitaloff, Francine Mugneret, Emmanuelle Clappier, J van den Akker, J Soulier, C Graux, Yves Benoit, Jan Cools, Carine Gervais, Franki Speleman, Pascale Cornillet-Lefebvre, Marie-Pierre Pages, C Chalas, Dominique Leroux, N. Van Roy, Christine Perot, Pierre Heimann, Roland Berger, Center for Medical Genetics [Ghent], Ghent University Hospital, Laboratoire de Biochimie Génétique, Hôpital Robert Debré, Laboratoire d'Hématologie, CHU Strasbourg, CHU Bretonneau, Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire Central d'Anatomie et de Cytologie Pathologiques [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de Génétique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier de Versailles André Mignot (CHV), Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Génétique [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Bases moléculaires de la progression tumorale -Groupe de Recherche sur les Lymphomes, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR73, Centre for Medical genetics, Hôpital UCL-St Luc, Gvh et Gvl : Physiopathologie Chez l'Homme et Chez l'Animal, Incidence et Role Therapeutique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Medical Genetics, Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB)-Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Centre for Molecular Diagnostics, Department of Pediatric Hematology/Oncology, Department of Human Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre for Human Genetics, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre for Medical Genetics, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Dijon (CHU Dijon), Laboratoire de Cytopathologie, Hôpital Edouard Herriot, Laboratoire de Génétique, CHU Nancy, Institut Paoli Calmettes, CHU Versailles, Centre Hospitalier de Versailles (CHV), CHU Reims, Hôpital Robert Debré - CHU Reims, Service de génétique, CHU Caen - Hôpital Clémenceau, Université Joseph Fourier - Grenoble 1 (UJF) - Institut National de la Santé et de la Recherche Médicale (INSERM) - IFR73, Université Paris Diderot - Paris 7 (UP7) - Institut National de la Santé et de la Recherche Médicale (INSERM), University Hospital Erasme, Hôpital Necker - Enfants malades, Assistance publique - Hôpitaux de Paris (AP-HP) - Université Paris Descartes - Paris 5 (UPD5), Hôpital Purpan, and Duley, Samuel

Subjects
Male, Cancer Research, Receptors, Antigen, T-Cell, alpha-beta, [SDV.GEN] Life Sciences [q-bio]/Genetics, MESH: Receptor, Notch1, Translocation, Genetic, 0302 clinical medicine, Immunophenotyping, MESH: Child, Leukemia-Lymphoma, Adult T-Cell, MESH: Leukemia-Lymphoma, Adult T-Cell, Receptor, Notch1, Child, Chromosomal inversion, 0303 health sciences, MESH: Middle Aged, MESH: Receptors, Antigen, T-Cell, alpha-beta, hemic and immune systems, Hematology, Middle Aged, MESH: Gene Rearrangement, T-Lymphocyte, MESH: Translocation, Genetic, 3. Good health, Oncology, 030220 oncology & carcinogenesis, Female, Chromosome Deletion, Adult, Transcriptional Activation, medicine.medical_specialty, Adolescent, MESH: Immunophenotyping, MESH: Chromosome Deletion, chemical and pharmacologic phenomena, Chromosomal rearrangement, Biology, Gene Rearrangement, T-Lymphocyte, 03 medical and health sciences, Acute lymphocytic leukemia, MESH: Homeodomain Proteins, medicine, Humans, 030304 developmental biology, Homeodomain Proteins, MESH: Adolescent, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, T-cell receptor, Cytogenetics, MESH: Adult, Gene rearrangement, medicine.disease, Molecular biology, MESH: Male, Homeobox A10 Proteins, Chromosome Inversion, MESH: Inversion, Chromosome, MESH: Transcriptional Activation, MESH: Female, Comparative genomic hybridization
Abstract

International audience; Recently, we and others described a new chromosomal rearrangement, that is, inv(7)(p15q34) and t(7;7)(p15;q34) involving the T-cell receptor beta (TCRbeta) (7q34) and the HOXA gene locus (7p15) in 5% of T-cell acute lymphoblastic leukemia (T-ALL) patients leading to transcriptional activation of especially HOXA10. To further address the clinical, immunophenotypical and molecular genetic findings of this chromosomal aberration, we studied 330 additional T-ALLs. This revealed TCRbeta-HOXA rearrangements in five additional patients, which brings the total to 14 cases in 424 patients (3.3%). Real-time quantitative PCR analysis for HOXA10 gene expression was performed in 170 T-ALL patients and detected HOXA10 overexpression in 25.2% of cases including all the cases with a TCRbeta-HOXA rearrangement (8.2%). In contrast, expression of the short HOXA10 transcript, HOXA10b, was almost exclusively found in the TCRbeta-HOXA rearranged cases, suggesting a specific role for the HOXA10b short transcript in TCRbeta-HOXA-mediated oncogenesis. Other molecular and/or cytogenetic aberrations frequently found in subtypes of T-ALL (SIL-TAL1, CALM-AF10, HOX11, HOX11L2) were not detected in the TCRbeta-HOXA rearranged cases except for deletion 9p21 and NOTCH1 activating mutations, which were present in 64 and 67%, respectively. In conclusion, this study defines TCRbeta-HOXA rearranged T-ALLs as a distinct cytogenetic subgroup by clinical, immunophenotypical and molecular genetic characteristics.

Published
2006

5. Acute diarrhea in adults consulting a general practitioner in France during winter: incidence, clinical characteristics, management and risk factors

Author

Véronique Vaillant, Nathalie Jourdan-Da Silva, Thierry Blanchon, Christophe Arena, Cécile Souty, Laurent Varesi, Alessandra Falchi, Jean Arrighi, Thomas Hanslik, Katia Ambert-Balay, Roxane Chikhi-Brachet, Jean Pierre Amoros, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Observatoire Régionale de Santé de Corse (ORS Corse), Fédération Nationale des Observatoires de la Santé, Service de Virologie, Université Pascal Paoli (UPP), Institut de Veille Sanitaire (INVS), Laboratoire de sérologie-virologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), ANRS France Recherche Nord & sud Sida-hiv hépatites, Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), AP-HP, Service de Médecine Interne, Hôpital Ambroise Paré, F-92100, Boulogne Billancourt, France, Hôpital Ambroise Paré [AP-HP], Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Corse, Centre Hospitalier Universitaire de Dijon (CHU Dijon), Agence nationale de recherches sur le sida et les hépatites virales, Institut Pasteur [Paris] - Institut National de la Santé et de la Recherche Médicale (INSERM) - Institut de Recherche pour le Développement (IRD) - Centre National de Recherche Scientifique CNRS), UFR des sciences de la santé Simone-Veil, Université Versailles-Saint-Quentin-en-Yvelines, F-78000, Versailles, France, and AP-HP, Hôpital Ambroise Paré

Subjects
Adult, Male, Rotavirus, Diarrhea, Pediatrics, medicine.medical_specialty, Adolescent, viruses, medicine.disease_cause, Astrovirus, Young Adult, General Practitioners, Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Epidemiology, Humans, Medicine, Adults, Risk factor, Young adult, Aged, Caliciviridae Infections, Surveillance, biology, business.industry, Incidence, Incidence (epidemiology), Norovirus, Middle Aged, biology.organism_classification, 3. Good health, Gastroenteritis, Infectious Diseases, Acute Disease, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, France, Seasons, medicine.symptom, business, General practice, Research Article
Abstract

Background Data describing the epidemiology and management of viral acute diarrhea (AD) in adults are scant. The objective of this study was to identify the incidence, clinical characteristics, management and risk factors of winter viral AD in adults. Methods The incidence of AD in adults during two consecutive winters (from December 2010 to April 2011 and from December 2011 to April 2012) was estimated from the French Sentinelles network. During these two winters, a subset of Sentinelles general practitioners (GPs) identified and included adult patients who presented with AD and who filled out a questionnaire and returned a stool specimen for virological examination. All stool specimens were tested for astrovirus, group A rotavirus, human enteric adenovirus, and norovirus of genogroup I and genogroup II. Age- and sex-matched controls were included to permit a case–control analysis with the aim of identifying risk factors for viral AD. Results During the studied winters, the average incidence of AD in adults was estimated to be 3,158 per 100,000 French adults (95% CI [2,321 – 3,997]). The most reported clinical signs were abdominal pain (91.1%), watery diarrhea (88.5%), and nausea (83.3%). GPs prescribed a treatment in 95% of the patients with AD, and 80% of the working patients with AD could not go to work. Stool examinations were positive for at least one enteric virus in 65% (95% CI [57 – 73]) of patients with AD with a predominance of noroviruses (49%). Having been in contact with a person who has suffered from AD in the last 7 days, whether within or outside the household, and having a job (or being a student) were risk factors significantly associated with acquiring viral AD. Conclusions During the winter, AD of viral origin is a frequent disease in adults, and noroviruses are most often the cause. No preventable risk factor was identified other than contact with a person with AD. Thus, at the present time, reinforcement of education related to hand hygiene remains the only way to reduce the burden of disease. Electronic supplementary material The online version of this article (doi:10.1186/s12879-014-0574-4) contains supplementary material, which is available to authorized users.

Published
2014

6. Simultaneous investigation of influenza and enteric viruses in the stools of adult patients consulting in general practice for acute diarrhea

Author

Laurent Varesi, Véronique Vaillant, Alessandra Falchi, Roxane Chikhi-Brachet, Thomas Hanslik, Katia Balay, Thierry Blanchon, Jean Arrighi, Christophe Arena, Fabrice Carrat, Jean Pierre Amoros, Laboratoire de Virologie, Université Pascal Paoli (UPP), Agence Régionale de Santé de Corse (ARS), Observatoire de l'Environnement de la Corse, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département des maladies infectieuses, Institut de Veille Sanitaire (INVS), Centre National de Référence des virus entériques [CHU de Dijon] (CNR virus entériques), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), ANRS France Recherche Nord & sud Sida-hiv hépatites, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), BMC, Ed., Université de Corse Pascal Paoli, Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Dijon (CHU Dijon), Agence nationale de recherches sur le sida et les hépatites virales, Institut Pasteur [Paris] - Institut National de la Santé et de la Recherche Médicale (INSERM) - Institut de Recherche pour le Développement (IRD) - Centre National de Recherche Scientifique CNRS), Pharmacie - Santé Publique - Information Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Saint-Antoine [APHP], Médecine Interne, and Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)

Subjects
Male, Rotavirus, viruses, medicine.disease_cause, Feces, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Influenza A virus, 030212 general & internal medicine, Aged, 80 and over, 0303 health sciences, Stools, biology, Coinfection, virus diseases, Middle Aged, Orthomyxoviridae, Enteric virus, 3. Good health, Co-infection, Diarrhea, Infectious Diseases, Acute Disease, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, RNA, Viral, Female, France, Seasons, medicine.symptom, General practice, Adult, Virus, Astrovirus, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, Young Adult, Virology, Influenza, Human, medicine, Humans, RNA Viruses, lcsh:RC109-216, Aged, 030306 microbiology, Research, Adenoviruses, Human, Influenza A Virus, H3N2 Subtype, Norovirus, biology.organism_classification, medicine.disease, Influenza B virus, Case-Control Studies, Influenza virus, Mamastrovirus
Abstract

Background Gastrointestinal symptoms are not an uncommon manifestation of an influenza virus infection. In the present study, we aimed to investigate the presence of influenza viruses in the stools of adult patients consulting their general practitioner for uncomplicated acute diarrhea (AD) and the proportion of concurrent infections by enteric and influenza viruses. Method A case-control study was conducted from December 2010 to April 2011. Stool specimens were collected and tested for influenza viruses A (seasonal A/H3N2 and pandemic A/H1N1) and B, and for four enteric viruses (astrovirus, group A rotavirus, human enteric adenovirus, norovirus of genogroups I – NoVGI - and genogroup II - NoVGII). Results General practitioners enrolled 138 cases and 93 controls. Of the 138 stool specimens collected, 92 (66.7%) were positive for at least one of the four enteric viruses analysed and 10 (7.2%) tested positive for one influenza virus. None of these 10 influenza positive patients reported respiratory symptoms. In five influenza-positive patients (3.6%), we also detected one enteric virus, with 4 of them being positive for influenza B (2 had co-detection with NoVGI, 1 with NoVGII, and 1 with astrovirus). None of the 93 controls tested positive for one of the enteric and/or other influenza viruses we investigated. Conclusions In this study we showed that the simultaneous detection of influenza and enteric viruses is not a rare event. We have also reported, for the first time in general practice, the presence of seasonal and pandemic influenza viruses in the stools of adult patients consulting for uncomplicated AD. A simultaneous investigation of enteric and influenza viruses in patients complaining of gastrointestinal symptoms could be useful for future studies to better identify the agents responsible for AD.

Published
2012

7. Suffering among carers working in critical care can be reduced by an intensive communication strategy on end-of-life practices

Author

Jean-Pierre Quenot, Arnaud Pavon, Jean-Philippe Rigaud, Sébastien Prin, Bernard Blettery, Nicolas Jacquiot, Pierre Emmanuel Charles, Saber Barbar, Mael Hamet, Grégoire Moutel, Christian Hervé, Service de Réanimation Médicale (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Réanimation Polyvalente, Centre hospitalier de Dieppe, Laboratoire d'éthique médicale et médecine légale (LEM), Université Paris Descartes - Paris 5 (UPD5), Centre Hospitalier Universitaire de Dijon (CHU Dijon), Centre Hospitalier de Dieppe, and Duchange, Nathalie

Subjects
Adult, Male, medicine.medical_specialty, Population, Burnout, Critical Care and Intensive Care Medicine, Article, Hospitals, University, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Nursing, 030202 anesthesiology, Intensive care, Anesthesiology, Surveys and Questionnaires, Depersonalization, Health care, medicine, Medical Staff, Hospital, Humans, 030212 general & internal medicine, education, Emotional exhaustion, Depression (differential diagnoses), education.field_of_study, Terminal Care, business.industry, communication, Middle Aged, [SDV.ETH] Life Sciences [q-bio]/Ethics, critical care organisation, ethics, 3. Good health, [SDV.ETH]Life Sciences [q-bio]/Ethics, Intensive Care Units, Physical therapy, Female, Interdisciplinary Communication, France, medicine.symptom, business, Stress, Psychological
Abstract

International audience; PURPOSE: Burnout syndrome (BOS) has frequently been reported in healthcare workers, and precipitating factors include communication problems in the workplace and stress related to end-of-life situations. We evaluated the effect of an intensive communication strategy on BOS among caregivers working in intensive care (ICU). METHODS: Longitudinal, monocentric, before-and-after, interventional study. BOS was evaluated using the Maslach Burnout Inventory (MBI) and depression using the Centre for Epidemiologic Studies Depression Scale (CES-D) in 2007 (period 1) and 2009 (period 2). Between periods, an intensive communication strategy on end-of-life practices was implemented, based on improved organisation, better communication, and regular staff meetings. RESULTS: Among 62 caregivers in the ICU, 53 (85%) responded to both questionnaires in period 1 and 49 (79%) in period 2. We observed a significant difference between periods in all three components of the MBI (emotional exhaustion, p = 0.04; depersonalization p = 0.04; personal accomplishment, p = 0.01). MBI classified burnout as severe in 15 (28%) caregivers in period 1 versus 7 (14%) in period 2, p

Published
2012

8. EFFECTS OF INTRA-ARTICULAR INJECTIONS OF HYLAN GF-20 ON SERUM AND URINE BIOMARKERS IN PATIENTS WITH KNEE OSTEOARTHRITIS: THE BIOVISCO STUDY

Author

Conrozier, T., Chevalier, X., Balblanc, J.-C., Richette, P., Rannou, François, Mulleman, D., Maillet, B., Maillefert, J.-F., Mathieu, P., Henrotin, Y., Vignon, E., Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Lariboisière - Université Paris Diderot - Paris 7 (UP7), CHU Cochin [APHP], Génétique, Immunothérapie, Chimie et Cancer (GICC), Université François Rabelais - Tours - Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Dijon (CHU Dijon), Cambefort, Jeanne, Université de Tours-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), and CHU Cochin [AP-HP]

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

9. Pharmacological treatment (biotherapy excluded) of peripheral psoriatic arthritis: Development of recommendations for clinical practice based on data from the literature and experts opinion

Author

Jacques Tebib, Xavier Le Loët, Thierry Schaeverbeke, Philippe Gaudin, Alain Saraux, Philippe Goupille, Carine Salliot, René Marc Flipo, Bernard Combe, Pascal Claudepierre, Daniel Wendling, Emmanuelle Dernis, Alain Cantagrel, Carle Paul, F. Lavie, Jean-Francis Maillefert, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Hôpital Lapeyronie [Montpellier] (CHU), Cambefort, Jeanne, Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie, Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Service de Rhumatologie, Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de rhumatologie [CHU Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service d'immunologie et rhumatologie, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Bordeaux [Bordeaux], Service de rhumatologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Cochin [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Lariboisière - Université Paris Diderot - Paris 7 (UP7), Centre Hospitalier Universitaire de Dijon (CHU Dijon), Génétique, Immunothérapie, Chimie et Cancer (GICC), Université François Rabelais - Tours - Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Henri Mondor - Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Université Joseph Fourier - Grenoble 1 (UJF) - CHU Grenoble, CHU Bordeaux [Bordeaux] - Groupe hospitalier Pellegrin, Hôpital Lapeyronie, and Université Montpellier 1 (UM1) - Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier) - Hôpital Lapeyronie

Subjects
MESH: Antirheumatic Agents, [SDV]Life Sciences [q-bio], Alternative medicine, Recommendations, Placebos, 0302 clinical medicine, MESH: Practice Guidelines as Topic, Azathioprine, MESH: Arthritis, Psoriatic, 030212 general & internal medicine, MESH: Advisory Committees, computer.programming_language, Randomized Controlled Trials as Topic, Evidence-Based Medicine, Anti-Inflammatory Agents, Non-Steroidal, MESH: Follow-Up Studies, MESH: Anti-Inflammatory Agents, Non-Steroidal, 3. Good health, Clinical Practice, [SDV] Life Sciences [q-bio], MESH: Joints, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Antirheumatic Agents, Psoriatic arthritis, Practice Guidelines as Topic, Leflunomide, MESH: Expert Testimony, medicine.medical_specialty, Advisory Committees, MEDLINE, MESH: Placebos, Pharmacological treatment, 03 medical and health sciences, Rheumatology, medicine, Humans, Hospitals, Teaching, Expert Testimony, Glucocorticoids, MESH: Azathioprine, 030203 arthritis & rheumatology, MESH: Humans, Spondylarthropathy, Task force, business.industry, Arthritis, Psoriatic, Everyday clinical practice, Isoxazoles, MESH: Hospitals, Teaching, medicine.disease, Sulfasalazine, Treatment, MESH: Randomized Controlled Trials as Topic, Methotrexate, MESH: Isoxazoles, Family medicine, Physical therapy, Joints, business, MESH: Glucocorticoids, computer, Delphi, Rheumatism, MESH: Evidence-Based Medicine, Follow-Up Studies
Abstract

International audience; Objectives: To develop recommendations about treatment (except anti-TNF agents) of psoriatic arthritis with peripheral joint involvement (PsA) seen in everyday practice, using evidence from the literature, supplemented with expert opinion when needed. Methods: The recommendations were based on evidence from the literature. First, a scientific committee used a Delphi procedure to select five focal points of interest. Then, a literature task force looked for relevant publications in the following: Cochrane, Pubmed, and Ovid databases and abstracts from the French Society for Rheumatology, European League against Rheumatism and American College of Rheumatology. Based on the data from these publications, recommendations were drafted and then validated by a group of 68 experts. The strength of each recommendation was determined, as well as the extent of agreement among the experts. Results: The evidence extracted from 73 selected papers was presented to experts during interactive workshops. At the end of the workshops, the experts drafted six recommendations, which were then validated by a final vote including all participants. These six recommendations displayed various strength from B to D. Conclusion: These recommendations should help to improve practice uniformity and, ultimately, to improve the management of PsA in France. (C) 2009 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.

Published
2009

10. Interposition of a gastric pouch between ileum and anus after proctocolectomy: long-term results in 3 patients

Author

Pablo Ortega-Deballon, Rezkallah Hareth, Patrick Rat, Olivier Facy, Giovanni Di-Giacomo, Nicolas Cheynel, Ortega Deballon, Pablo, Service de Chirurgie Digestive, Cancérologique, Générale, Endocrinienne et Urgences (CHU de Dijon), and Centre Hospitalier Universitaire de Dijon (CHU Dijon)

Subjects
Adult, Male, medicine.medical_specialty, Gastroplasty, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, medicine.medical_treatment, Rectum, Colonic Pouches, Anastomosis, Ileostomy, Medicine, Humans, business.industry, Proctocolectomy, Proctocolectomy, Restorative, digestive, oral, and skin physiology, Middle Aged, Anus, medicine.disease, Ulcerative colitis, Surgery, medicine.anatomical_structure, Treatment Outcome, Adenomatous Polyposis Coli, Quality of Life, Colitis, Ulcerative, Female, Pouch, business, Follow-Up Studies
Abstract

International audience; BACKGROUND: After proctocolectomy, ileal pouch-anal anastomosis may not be feasible, especially in the case of desmoid tumor or after failed ileal pouch-anal anastomosis requiring excision of the pouch. We designed a gastric pouch interposed between the terminal ileum and the anus to avoid a permanent ileostomy for these patients. Long-term results and quality of life with this technique remain unknown. METHODS: After proctocolectomy, ileal pouch-anal anastomosis was not feasible or had failed in 3 patients (2 with familial adenomatous polyposis and 1 with ulcerative colitis; 40, 49, and 50 years of age, respectively). Of these patients, 2 had undergone end ileostomy 7 and 8 years previously. A pouch was created using the left half of the gastric fundus, supplied through the right gastroepiploic vessels; the pouch was anastomosed proximally to the terminal ileum and distally to the anus. Diverting ileostomy was performed in all patients. RESULTS: After a mean follow-up of 6 years, all 3 patients were highly satisfied with the operation and described their quality of life as good. The median stool frequency during the day and night were 6 and 1, respectively. No patient reported incontinence or urgency. Of the 3 patients, 2 had minimal soiling with gastric juice; 1 patient had anastomotic ulcers with bleeding requiring resection with reanastomosis. All of the patients needed long-term proton pump inhibitor therapy and topical perianal treatment to prevent skin burning. CONCLUSION: Inter-ileoanal gastroplasty is a surgical salvage technique that can avoid a permanent ileostomy. The procedure provides a good quality of life for patients with unfeasible or failed ileal pouch.

Published
2009

11. Refractory bleeding from peptic ulcers: is there still a role for surgery?

Author

Romaric Loffroy, Boris Guiu, Guiu, Boris, Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon), and Centre Hospitalier Universitaire de Dijon (CHU Dijon)

Subjects
medicine.medical_specialty, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hepatology and Gastroenterology, business.industry, medicine.medical_treatment, General surgery, Peptic, Gastroenterology, MEDLINE, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Surgery, Refractory, medicine, Embolization, business, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2009

12. Arterial embolization is the best treatment for pancreaticojejunal anastomotic bleeding after pancreatoduodenectomy

Author

Boris Guiu, Romaric Loffroy, Guiu, Boris, Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon), and Centre Hospitalier Universitaire de Dijon (CHU Dijon)

Subjects
medicine.medical_specialty, medicine.diagnostic_test, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hepatology and Gastroenterology, business.industry, medicine.medical_treatment, Arterial Embolization, Gastroenterology, General Medicine, Anastomosis, Pancreaticoduodenectomy, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Surgery, medicine.anatomical_structure, Hemostasis, Angiography, medicine, Radiology, Embolization, business, Sandwich technique, Artery
Abstract

International audience; Massive pancreaticojejunal anastomotic bleeding, mainly from the gastroduodenal stump, is one of the most common complications of pancreatoduodenectomy. Selective angiography should be systematically the first step of investigative procedure in such situations. Pharmacoarteriography may be used if the bleeding point is not spontaneously identified, and allows safe and effective treatment with transcatheter arterial embolization compared to blind open surgical hemostasis. Coil embolization of the common or proper hepatic artery on either side of the bleeding point with "sandwich technique" is then the preferred technique to prevent retrograde filling. Surgery should be performed only as a last resort.

Published
2009

13. Re: Effectiveness of coil embolization in angiographically detectable versus non-detectable sources of upper gastrointestinal hemorrhage

Author

Basem Abualsaud, Romaric Loffroy, Boris Guiu, Guiu, Boris, Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon), and Centre Hospitalier Universitaire de Dijon (CHU Dijon)

Subjects
Male, medicine.medical_specialty, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hepatology and Gastroenterology, business.industry, Angiography, Embolization, Therapeutic, Sensitivity and Specificity, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Upper Gastrointestinal Tract, Text mining, Treatment Outcome, medicine, Upper gastrointestinal, Humans, Radiology, Nuclear Medicine and imaging, Female, Radiology, Cardiology and Cardiovascular Medicine, business, Gastrointestinal Hemorrhage, ComputingMilieux_MISCELLANEOUS, Coil embolization, Aged, Retrospective Studies
Abstract

International audience

Published
2009

14. Ethical issues arising from the requirement to sign a consent form in palliative care

Author

Irène Purssell-François, Isabelle Plu, Grégoire Moutel, Christian Hervé, Françoise Ellien, Service de médecine légale (Institut médico-légal et Unité médico-judiciaire) (CHU de Dijon), Centre Hospitalier Universitaire de Dijon (CHU Dijon), Laboratoire d'éthique médicale et médecine légale (LEM), Université Paris Descartes - Paris 5 (UPD5), Réseau SPES, Réseau Soins Palliatifs Essonne Sud, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), and Duchange, Nathalie

Subjects
Health (social science), Palliative care, Attitude of Health Personnel, education, MEDLINE, Legislation, Article, Consent Forms, 03 medical and health sciences, 0302 clinical medicine, Arts and Humanities (miscellaneous), Nursing, 030502 gerontology, Health care, Medicine, Humans, 030212 general & internal medicine, Physician-Patient Relations, Ethical issues, business.industry, Health Policy, Palliative Care, Sign (semiotics), Continuity of Patient Care, Patient Acceptance of Health Care, [SDV.ETH] Life Sciences [q-bio]/Ethics, 3. Good health, [SDV.ETH]Life Sciences [q-bio]/Ethics, Issues, ethics and legal aspects, Guardian, Psychological aspects, France, 0305 other medical science, business
Abstract

International audience; French healthcare networks aim to help healthcare workers to take care of patients by improving cooperation, coordination and the continuity of care. When applied to palliative care in the home, they facilitate overall care including medical, social and psychological aspects. French legislation in 2002 required that an information document explaining the functioning of the network should be given to patients when they enter a healthcare network. The law requires that this document be signed. Ethical issues arise from this legislation with regard to the validity of the signature of dying patients. Signature of the consent form by a guardian or trustee, a designated person--the Person of Trust--transforms the doctor-patient relationship into a triangular doctor-patient-third-party relationship.

Published
2008

15. Visual documentation of oral consent: a new method of informed consent before major gigantomastia reduction for an illiterate population

Author

Alan Lile, Christian Hervé, Khadija Chahraoui, Gabriel Malka, Alain M. Danino, Grégoire Moutel, Duchange, Nathalie, Service Chirurgie Maxillo-Faciale - Stomatologie - Chirurgie Plastique Réparatrice et Esthétique - Chirurgie de la main (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire d'éthique médicale et médecine légale (LEM), Université Paris Descartes - Paris 5 (UPD5), Department of Plastic and Reconstructive Surgery, and Centre Hospitalier Universitaire de Dijon (CHU Dijon)

Subjects
medicine.medical_specialty, medicine.medical_treatment, Mammaplasty, Population, Anxiety, Treatment Refusal, 03 medical and health sciences, 0302 clinical medicine, Documentation, Informed consent, MESH: Audiovisual Aids, MESH: Informed Consent, Medicine, Humans, 030212 general & internal medicine, education, Reduction (orthopedic surgery), ComputingMilieux_MISCELLANEOUS, education.field_of_study, Informed Consent, MESH: Humans, MESH: Treatment Refusal, Audiovisual Aids, MESH: Anxiety, business.industry, Communication, [SDV.ETH] Life Sciences [q-bio]/Ethics, [SDV.ETH]Life Sciences [q-bio]/Ethics, 030220 oncology & carcinogenesis, Family medicine, Educational Status, MESH: Mammaplasty, Surgery, Female, MESH: Communication, business, MESH: Educational Status, MESH: Female
Abstract

International audience

Published
2006

16. Transcatheter Arterial Embolization for Bleeding Peptic Ulcers: Is the Use of Coils Alone the Best Choice?

Author

Denis Krausé, Romaric Loffroy, Boris Guiu, Guiu, Boris, Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon), and Centre Hospitalier Universitaire de Dijon (CHU Dijon)

Subjects
medicine.medical_specialty, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hepatology and Gastroenterology, medicine.diagnostic_test, business.industry, Arterial Embolization, medicine.medical_treatment, Gastroenterology, medicine.disease, Inferior mesenteric artery, [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Surgery, Gastroduodenal artery, medicine.anatomical_structure, medicine.artery, Angiography, medicine, Duodenum, Superior mesenteric artery, Upper gastrointestinal bleeding, Embolization, Radiology, business, ComputingMilieux_MISCELLANEOUS
Abstract

logic agents such as intra-arterial vasodilators during the procedures to increase the probability of finding visible active bleeding? Is it really the ‘superior mesenteric artery’ instead of ‘inferior mesenteric artery’ in the embolization technique section of the article? Furthermore, a major limitation of this study is the small number of patients which leads to a high risk of type II error. In particular, no meaningful conclusions can be drawn regarding the sandwich technique (‘frontdoor-backdoor principle’) for coil occlusion of the gastroduodenal artery used by the authors. We recently reported our results obtained during nearly 10 years of experience with arterial embolization to treat refractory massive bleeding from gastroduodenal ulcers [4] . We had 60 patients, the largest case series in the literature. Using coils alone to occlude the gastroduodenal artery significantly predicted early rebleeding (within 30 days) by univariate analysis (p = 0.003) and by multivariate analysis (p = 0.022). We therefore advocate the use of gelatin particles between the proximal and distal coils in the trunk of the gastroduodenal artery. In conclusion, we do not recommend the use of coils as the only embolic agent Dear Sir, We read with great interest the article by Van Vugt et al. [1] published recently in Digestive Surgery and reporting emergent gastroduodenal artery embolization in patients with upper gastrointestinal bleeding from duodenal peptic ulcers. We have several comments and questions. Arterial embolization is now accepted as the salvage treatment of choice for acute bleeding from duodenal ulcers despite endoscopic treatment. Many published studies confirm the feasibility of this approach, and the high technical and clinical success rates range from 91 to 100% and from 63 to 100%, respectively, in all case series including more than 20 patients over the last decade [2, 3] , even if factors that influence the angiographic outcome are not well documented. First, we are surprised that in this study 75% of patients had signs of active bleeding upon angiography (i.e. extravasation of contrast medium) whereas catheterization of the superior mesenteric artery seems not to have been performed. In our experience, the extravasation rate is much lower despite systematic selective catheterization of the celiac trunk and the gastroduodenal and superior mesenteric arteries in all cases. Did the authors use pharmacoPublished online: July 3, 2009

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results